insPIred™ - Biotest Pharmaceuticals Launches Program for Primary Immunodeficiency (PI) Community

Jun 27, 2013, 15:00 ET from Biotest Pharmaceuticals Corporation

BOCA RATON, Fla., June 27, 2013 /PRNewswire/ -- Biotest Pharmaceuticals Corporation ("BPC"), a wholly owned US subsidiary of Biotest AG, (Dreieich Germany), announced the launch of insPIred™, a comprehensive patient education, resource and support program for the PI community. The inspiration for the program was sparked by the passion and commitment of the Primary Immunodeficiency (PI) community. BPC unveiled the program during the Immune Deficiency Foundation's (IDF) Biannual meeting being held in Baltimore, Maryland.

InsPIred provides the PI community with much needed information and resources pertaining to Primary Immunodeficiency, or PI. The program is intended to:

  • Broaden overall awareness and understanding of PI to help with diagnosis of the disease,
  • Educate patients about available PI treatment options
  • Provide day-to-day motivation
  • Help patients and their families cope with PI

"This program is part of Biotest's continued commitment to the PI community with the purpose of identifying unmet needs and working with individuals with PI to find solutions. The enthusiasm and vitality of individuals with PI insPIred BPC to launch its all-embracing patient support program," said Jordan Siegel, Chief Executive Officer of BPC. "It is BPC's goal to offer more than a safe and efficacious treatment for the PI community. Offering support for those patients, physicians and nurses dealing with various aspects of PI is very important to us."

InsPIred is a broad reaching program that will ultimately include partnerships and sponsorships specifically designed for patients and related parties. Douglas Loock, Vice President of Marketing & Sales stated: "We will provide specific patient information in the form of brief brochures such as 'Me and My PI' and at the same time continue to work closely with the various foundations advocating for patients with PI.  With the recent launch of BIVIGAM®, BPC is looking forward to interacting closely with the PI community."

Through the essential input from patients and healthcare providers, BPC will continue to work closely with the PI community to further expand the program. For details on the various aspects of the insPIred program and to be informed of changes, please register for our mailing list at:

BPC is the manufacturer of BIVIGAM. BIVIGAM [Immune Globulin Intravenous (Human), 10% Liquid] utilizes a non-sugar-based stabilizer - Glycine that is available in 50 mL and 100 mL tamper evident vials. The product uses a label with an integrated hanger and the packaging material is latex free. For more information, please visit

About Biotest Pharmaceuticals Corporation
Biotest Pharmaceuticals Corporation was created as a wholly-owned US subsidiary of Biotest AG in December 2007. Innovative technologies and a sharp focus on safety are incorporated into every facet of the business. From plasma collection to product manufacturing and distribution – from nature for life – Biotest Pharmaceuticals Corporation is committed to maintaining high standards of excellence.  With further questions, please contact the Customer Support at 1-800-458-4244.

About Biotest AG
Biotest is a provider of pharmaceutical and biotherapeutic drugs. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialised primarily in the areas of application of clinical immunology, haematology and intensive medicine. In its Plasma Protein segment, Biotest develops and markets immunoglobulins, coagulation factors and albumins based on human blood plasma. These are used for diseases of the immune and haematopoietic systems. In the Biotherapeutic segment, Biotest researches into the clinical development of monoclonal antibodies, including in the indications of rheumatoid arthritis and cancer of plasma cells. Biotest has more than 1.800 employees worldwide. The preference shares of Biotest AG are listed in the SDAX on the Frankfurt stock exchange.

This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and assets position of Biotest AG and its subsidiaries. These statements are based on current plans, estimates, forecasts and expectations of the company and are thus subject to risks and elements of uncertainty that could result in significant deviation of actual developments from expected developments. The forward-looking statements are only valid at the time of publication. Biotest does not intend to update the forward-looking statements and assumes no obligation to do so.

SOURCE Biotest Pharmaceuticals Corporation